<DOC>
	<DOCNO>NCT02915445</DOCNO>
	<brief_summary>This study patient nasopharyngeal carcinoma breast cancer . As epithelial cell adhesion molecule ( EpCAM ) well characterize molecule closely poor prognosis tumor metastasis invasion . Many therapy target EpCAM show benefit cancer patient . This study determine safety engineer T cell arm chimeric antigen receptor ( CAR-T ) recognize EpCAM . At time , efficacy evaluate criterion RECIST . The EpCAM CAR-T produce lentiviral transduction 3rd generation CAR gene . Different cohort patient receive EpCAM CAR-T dose-escalating manner . This study find large dose EpCAM CAR-T , learn adverse effect find whether experimental intervention might help patient nasopharyngeal carcinoma breast cancer .</brief_summary>
	<brief_title>EpCAM CAR-T Treatment Nasopharyngeal Carcinoma Breast Cancer</brief_title>
	<detailed_description>In study , original tumor tissue specimen stain determine expression level EpCAM . Only patient tumor high expression level include . 50-100ml blood drawn get enough CD3 T cell least 2x10^7 . After separation , PBMC activate via antibody CD3 CD28 transduce lentivirus bearing EpCAM CAR gene . Then EpCAM CAR-T cell proliferate 10-100 fold infusion . The produced cell freeze infuse available . Included patient precondition cyclophosphamide lymphodepletion level white blood cell lymphocytes normal . Infusion T cell , least 1 day lymphodepletion , dose escalate begin low level . If first level proven safe , next level proceed . Once severe side effect observe , dose lower dose stop . During infusion , patient take care cardiogram monitor . Blood draw take infusion , 4h infusion day 4 , 7 , 14 , 30 , 60 , 90 , 120 , 150 , 180 determine presence CAR-T cell . At time , cytokine include IL-6 , TNF-alpha IFN-gamma C-reactive protein level determine . Routine imaging study proceed . To see whether long-term side effect therapy , patient receive CAR-T cell follow least 15 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion time procurement : Recurrent refractory nasopharyngeal carcinoma breast cancer . Karnofsky score great equal 60 . Informed consent explain , understood sign subject/guardian . Subject/guardian give copy inform consent Treatment Inclusion criterion : Recurrent refractory EpCAMpositive nasopharyngeal carcinoma breast cancer determine Immunohistochemistry ( IHC ) RTPCR . EpCAM expression tumor IHC great equal grade 2 great equal 2+ intensity score . Wherein grade defines : Grade 0 : staining ; Grade 1 : 125 % ; Grade 2 : 2650 % Grade 3 : 51100 % cell stain EpCAM intensity score : negative ; 1+ ; 2+ 3+ use breast cancer standard array guide intensity . Age ≥ 18 year Life expectancy ≥ 6 week Karnofsky score ≥ 60 Bilirubin less equal 3x normal , AST le equal 5x normal , ALT le equal 5x , serum creatinine less equal 2x upper limit normal age , Hgb great equal 8.0 Pulse oximetry great equal 90 % room air . Sexually active subject must willing utilize one effective birth control method 6 month T cell infusion . The male partner use condom . Available autologous transduce T lymphocytes great equal 20 % expression EpCAM CAR determine flowcytometry kill EpCAMpositive target great equal 20 % cytotoxicity assay . Subjects investigational antineoplastic therapy two week prior entry study . Cyclophosphamide allow 72 hour preinfusion . Dexamethasone total dose 2 mg per day allow medically indicate . Informed consent explain , understood sign research subjects/guardian . Subject/guardian give copy inform consent . Exclusion Criteria time procurement : Known HIV positivity . Treatment Severe intercurrent infection . Known HIV positivity . Pregnant lactating . History hypersensitivity reaction murine proteincontaining product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>EpCAM CAR-T , solid tumor , cancer immunotherapy</keyword>
</DOC>